© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
June 10, 2019
The results of the phase II trial examining combination immunotherapy were presented during the ASCO 2019 meeting.
Findings from a pooled analysis of two phase III trials, COMBI-d and COMBI-v, centered on outcomes with first-line dabrafenib plus trametinib vs either agent alone.
June 07, 2019
Data from the largest randomized neoadjuvant trial in resectable stage IIIB–IVM1a melanoma to date were presented at ASCO 2019.
The investigators looked at whether whole-brain radiotherapy improved outcomes in patients with melanoma brain metastasis.
June 05, 2019
A large international study looked at whether pregnancy is safe after breast cancer for women who have a BRCA mutation.
COMBI-i tested the anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in previously untreated patients with advanced BRAF V600–mutant melanoma.
The updated survival results from the COLUMBUS trial represent a promising new treatment option for patients with BRAF V600–mutant melanoma.
A phase III study comparing the efficacy and safety of nivolumab plus an experimental interleukin-2–based drug vs nivolumab alone in patients with metastatic melanoma is now enrolling patients.
June 04, 2019
Researchers tested standard-dose pembrolizumab plus ipilimumab at 50-mg or 100-mg doses in patients with previously untreated advanced melanoma.
Researchers tested a combination regimen of bevacizumab with carboplatin and paclitaxel as a first-line treatment for patients with advanced mucosal melanoma.